Eli Lilly is expanding its India specialty pipeline by making Alzheimer’s disease a central bet, alongside obesity and metabolic therapies. The company launched Lormalzi (donanemab), a once-monthly intravenous treatment aimed at amyloid plaques driving early symptomatic Alzheimer’s, unlike older drugs that mainly ease symptoms. Lormalzi is priced at Rs 91,688 per 350 mg vial, delivered every four weeks for up to 18 months, and will roll out through hospitals and pharmacies with an alternative access program. Lilly also cites diagnosis delays, expecting blood-based biomarkers to help.
IIT Madras scientists are using indigenous proprietary technology to create extremely high-resolution brain images by slicing tissue down to a fraction of a human hair. The resulting image bank is reported to be several times sharper than advanced MRI, offering new clues about how Alzheimer’s and Parkinson’s begin and progress—potentially accelerating earlier detection and better treatments.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
